Itratuf SB 130mg Capsule contains Itraconazole 130mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. The capsule formulation ensures optimal bioavailability when taken with food, enhancing systemic absorption. Itratuf SB is particularly effective against infections caused by Candida species, dermatophytes, and certain molds. It is prescribed for both superficial and systemic fungal infections, especially in patients who are intolerant or resistant to other antifungal therapies. Dosage and duration depend on the type and severity of infection, and therapy should be guided by clinical response and laboratory findings. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully monitored due to itraconazole’s effect on cytochrome P450 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Itratuf SB 130mg Capsule should be used under medical supervision to ensure safety and efficacy.